SRA - Scientist - Tumor Immunology - Hayward, CA | Biospace
Get Our FREE Industry eNewsletter

SRA - Scientist - Tumor Immunology

PACT Pharma, Inc.

Location:
Hayward, CA
Posted Date:
9/7/2017
Position Type:
Full time
Job Code:
PP-TI
Salary:
TBD
Required Education:
Bachelors Degree
Areas of Expertise Desired:
Assay, Assay Development, Associate, Cell, Cytometry, Drug Discovery, Elisa, Flow Cytometry, Immunology, Lab Assistant, Lab Technician, Laboratory, Oncology, Pharmaceutical, Research, Research Associate: Cell Biology, Scientist Immunology, Scientist Oncology, Senior Research Associate,

Job Description

The ideal candidate will be experienced in immuno-oncology. She/he will be responsible for the design and execution of critical path experiments for the development of the optimal strategy for the generation of CD3 neoE TCR transgenic cells for adoptive cell therapy (ACT). This research will focus on supporting studies to identifying TCR requirements for optimal functional avidity and the T cell profile for the most favorable homing and longevity. The candidate should enjoy operating in an exceptionally dynamic and cooperative environment.
Responsibilities:
•   The candidate should be highly proficient in state of the art techniques for characterizing T cell phenotype and measuring T cell functionality (antigen-specific killing assays, cytokine production, trafficking), proliferation and viability.
•   She/he must have excellent organizational skills and should be able to communicate clearly and concisely, both verbally and in the form of written reports.

Requirements

Minimum Qualifications:
•   The ideal candidate will hold a Bachelor degree with 5+ year experience; a Master degree with 2+ year experience; or PhD, with career focus in immunology or immuno-oncology. Industry experience is a plus.
•   She/he will have training that includes research on human tumors, preferably primary tumors and primary human T cells.
•   She/he must be proficient at cell-based bioassays, ELISA and flow cytometry.
•   Experience with in 3D tumor models is a plus.